ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 177 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2016. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $74,134,000 | +15.1% | 1,054,386 | +16.2% | 0.01% | +10.0% |
| Q3 2016 | $64,382,000 | +49.8% | 907,553 | +3.2% | 0.01% | +42.9% |
| Q2 2016 | $42,992,000 | -23.9% | 879,001 | -1.5% | 0.01% | -22.2% |
| Q1 2016 | $56,469,000 | -43.5% | 891,940 | +0.1% | 0.01% | -47.1% |
| Q4 2015 | $99,990,000 | +21.6% | 891,338 | +4.4% | 0.02% | +21.4% |
| Q3 2015 | $82,224,000 | +10.7% | 853,743 | +17.7% | 0.01% | +16.7% |
| Q2 2015 | $74,254,000 | +133.1% | 725,209 | +41.3% | 0.01% | +140.0% |
| Q1 2015 | $31,860,000 | +47.2% | 513,123 | +4.0% | 0.01% | +66.7% |
| Q4 2014 | $21,640,000 | -18.2% | 493,172 | +5.6% | 0.00% | -25.0% |
| Q3 2014 | $26,443,000 | +635.1% | 467,196 | +483.1% | 0.00% | +300.0% |
| Q2 2014 | $3,597,000 | -30.1% | 80,125 | -23.9% | 0.00% | 0.0% |
| Q1 2014 | $5,146,000 | – | 105,261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |